Radiation resistance of cancer stem cells: The 4 R's of radiobiology revisited

Stem Cells

Volumn 28, Issue 4, 2010, Pages 639-648

  Pajonk, Frank ^a   Vlashi, Erina ^a   McBride, William H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer stem cells; Cancer initiating cells; Radiation biology

Indexed keywords

NOTCH RECEPTOR; REACTIVE OXYGEN METABOLITE;

CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL CYCLE PROGRESSION; CELL PROTECTION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CELLULAR STRESS RESPONSE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; HYPOXEMIA; OXIDATIVE STRESS; RADIATION PROTECTION; RADIATION RESPONSE; RADIOSENSITIVITY; REOXYGENATION; REVIEW; SIGNAL TRANSDUCTION; TISSUE OXYGENATION; TREATMENT FAILURE; TUMOR GROWTH;

ANIMALS; DNA DAMAGE; DNA REPAIR; HUMANS; NEOPLASTIC STEM CELLS; OXIDATION-REDUCTION; RADIATION TOLERANCE;

EID: 77950972011     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.318     Document Type: Review

References (125)

1. Hewitt HB. Studies of the dissemination and quantitative transplantation of a lymphocytic leukaemia of CBA mice. Br J Cancer 1958;12(3):378-401.
2. Southam C, Brunschwig A. Quantitative studies of autotransplantation of human cancer. Preliminary report. Cancer 1961;14(5):971-978.
3. Reya T, Morrison SJ, Clarke MF et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414(6859):105-111.
4. Hill RP, Milas L. The proportion of stem cells in murine tumors. Int J Radiat Oncol Biol Phys 1989;16(2):513-518. (Pubitemid 19077222)
5. Clarke MF, Dick JE, Dirks PB et al. Cancer Stem Cells - Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells. Cancer Res 2006;66(19):9339-9344.
6. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367(6464):645-648. (Pubitemid 24067706)
7. Lane SW, Gilliland DG. Leukemia stem cells. Semin Cancer Biol 2009 [Epub ahead of print].
8. Chao MP, Seita J, Weissman IL. Establishment of a normal hematopoietic and leukemia stem cell hierarchy. Cold Spring Harb Symp Quant Biol 2008;73:439-449.
9. Trott KR. Tumour stem cells: the biological concept and its application in cancer treatment. Radiother Oncol 1994;30(1):1-5.
10. Hill RP. Identifying cancer stem cells in solid tumors: case not proven. Cancer Res 2006;66(4):1891-1895, discussion 1890.
11. Hill RP, Perris R. "Destemming" cancer stem cells. J Natl Cancer Inst 2007;99(19):1435-1440.
12. Park CY, Tseng D, Weissman IL. Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol Ther 2009;17(2):219-230.
13. Quintana E, Shackleton M, Sabel MS et al. Efficient tumour formation by single human melanoma cells. Nature 2008;456(7222):593-598.
14. Kummermehr JC. Tumour stem cells - the evidence and the ambiguity. Acta Oncol 2001;40(8):981-988.
15. Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-3988. (Pubitemid 36418143)
16. Schatton T, Murphy GF, Frank NY et al. Identification of cells initiating human melanomas. Nature 2008;451(7176):345-349.
17. Hemmati HD, Nakano I, Lazareff JA et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 2003;100(25):15178-15183. (Pubitemid 37518036)
18. Phillips TM, Kim K, Vlashi E et al. Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia 2007;9(12):1122-1129. (Pubitemid 350255350)
19. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/ CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006;98(24):1777-1785. (Pubitemid 46017929)
20. Woodward WA, Chen MS, Behbod F et al. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A 2007;104(2):618-623. (Pubitemid 46123074)
21. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63(18):5821-5828. (Pubitemid 37187480)
22. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 2004;432(7015):396-401. (Pubitemid 39551674)
23. Collins AT, Berry PA, Hyde C et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65(23):10946-10951. (Pubitemid 41713363)
24. Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67(3):1030-1037. (Pubitemid 46270758)
25. Fang D, Nguyen TK, Leishear K et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005;65(20):9328-9337. (Pubitemid 41508000)
26. Prince ME. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007;104:973-978. (Pubitemid 46154721)
27. Shimono Y, Zabala M, Cho RW et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009;138(3):592-603.
28. Zhu L, Gibson P, Currle DS et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009;457(7229):603- 607.
29. Barker N, Ridgway RA, van Es JH et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009;457(7229):608-611.
30. Pérez-Caro M, Cobaleda C, Gonzalez-Herrero I et al. Cancer induction by restriction of oncogene expression to the stem cell compartment. Embo J 2009;28(1):8-20.
31. Llaguno SA, Chen J, Kwon CH et al. Neural and cancer stem cells in tumor suppressor mouse models of malignant astrocytoma. Cold Spring Harb Symp Quant Biol 2008;73:421-426.
32. Bao S. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760. (Pubitemid 44949604)
33. Eramo A, Ricci-Vitiani L, Zeuner A et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006;13(7):1238-1241. (Pubitemid 43905604)
34. Chiou SH, Kao CL, Chen YW et al. Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor. PLoS One 2008;3(5):e2090.
35. Blazek ER, Foutch JL, Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007;67(1):1-5. (Pubitemid 44959518)
36. Chang CJ, Hsu CC, Yung MC et al. Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression. Biochem Biophys Res Commun 2009;380(2):236-242.
37. Holtz MS, Forman SJ, Bhatia R. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 2005;19(6):1034-1041. (Pubitemid 40862017)
38. Lu KH, Chen YW, Tsai PH et al. Evaluation of radiotherapy effect in resveratrol-treated medulloblastoma cancer stem-like cells. Childs Nerv Syst 2009;25(5):543-550.
39. Lomonaco SL, Finniss S, Xiang C et al. The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer 2009;125(3):717-722.
40. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008;10(2):R25.
41. Diehn M, Cho RW, Lobo NA et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458(7239):780-783.
42. Vlashi E, Kim K, Dealla DL et al. In-vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst 2009;101(5):350-359.
43. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008;8(7):545-554. (Pubitemid 351881850)
44. Withers HR, ed. The four R's of radiotherapy. New York: Academic Press, 1975. Lett JT AH, ed. Advances in radiation biology; No.5.
45. Steel GG, McMillan TJ, Peacock JH. The 5Rs of radiobiology. Int J Radiat Biol 1989;56(6):1045-1048.
46. Barker N, van Es JH, Kuipers J et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007;449(7165):1003-1007. (Pubitemid 350014593)
47. Mitchell JB, Russo A. The role of glutathione in radiation and drug induced cytotoxicity. Br J Cancer 1987;8:96-104. (Pubitemid 17108366)
48. Jang YY, Sharkis SJ. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the lowoxygenic niche. Blood 2007;110(8):3056-3063.
49. Olive PL. Detection of DNA damage in individual cells by analysis of histone H2AX phosphorylation. Methods Cell Biol 2004;75:355-373. (Pubitemid 39752532)
50. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 2006;98(24):1755-1757. (Pubitemid 46017927)
51. Ropolo M, Daga A, Griffero F et al. Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Mol Cancer Res 2009;7(3):383-392.
52. McCord AM, Jamal M, Williams ES et al. CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin Cancer Res 2009;15(16):5145-5153.
53. Al-Assar O, Muschel RJ, Mantoni TS et al. Radiation response of cancer stem-like cells from established human cell lines after sorting for surface markers. Int J Radiat Oncol Biol Phys 2009;75(4):1216-1225.
54. Alexander CM, Puchalski J, Klos KS et al. Separating stem cells by flow cytometry: reducing variability for solid tissues. Cell Stem Cell 2009;5(6):579-583.
55. Griguer CE, Oliva CR, Gobin E et al. CD133 is a marker of bioenergetic stress in human glioma. PLoS One 2008;3(11):e3655.
56. Clément V, Dutoit V, Marino D et al. Limits of CD133 as a marker of glioma self-renewing cells. Int J Cancer 2009;125(1):244-248.
57. Wang J, Sakariassen PO, Tsinkalovsky O et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008;122(4):761-768.
58. Sun Y, Kong W, Falk A et al. CD133 (Prominin) negative human neural stem cells are clonogenic and tripotent. PLoS One 2009;4(5):e5498.
59. Heideker J, Lis ET, Romesberg FE. Phosphatases, DNA damage checkpoints and checkpoint deactivation. Cell Cycle 2007;6(24):3058-3064.
60. Wang H, Hu B, Liu R et al. CHK1 affecting cell radiosensitivity is independent of non-homologous end joining. Cell Cycle 2005;4(2):300-303. (Pubitemid 41365338)
61. Wu Y, Kantake N, Sugiyama T et al. Rad51 protein controls Rad52-mediated DNA annealing. J Biol Chem 2008;283(21):14883-14892.
62. Charafe-Jauffret E, Ginestier C, Iovino F et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009;69(4):1302-1313.
63. Iwasa T, Okamoto I, Suzuki M et al. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 2008;14(20):6496-6504.
64. Chakravarti A, Zhai GG, Zhang M et al. Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004;23(45):7494-7506. (Pubitemid 39389691)
65. Rödel F, Hoffmann J, Distel L et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005;65(11):4881-4887. (Pubitemid 40740827)
66. Rödel F, Frey B, Leitmann W et al. Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys 2008;71(1):247-255. (Pubitemid 351491424)
67. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004;59(4):928-942. (Pubitemid 38834285)
68. Withers HR. Cell cycle redistribution as a factor in multifraction irradiation. Radiology 1975;114(1):199-202.
69. Arai F, Hirao A, Ohmura M et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004;118(2):149-161. (Pubitemid 38962572)
70. Wilson A, Laurenti E, Oser G et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 2008;135(6):1118-1129.
71. Wu M, Kwon HY, Rattis F et al. Imaging hematopoietic precursor division in real time. Cell Stem Cell 2007;1(5):541-554. (Pubitemid 350056405)
72. Korkaya H, Wicha MS. HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clin Cancer Res 2009;15(6):1845-1847.
73. Hoey T, Yen WC, Axelrod F et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5(2):168-177.
74. Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11(1):69-82. (Pubitemid 46054518)
75. Withers HR, Maciejewski B, Taylor JM et al. Accelerated repopulation in head and neck cancer. Front Radiat Ther Oncol 1988;22:105-110.
76. Bese NS, Sut PA, Ober A. The effect of treatment interruptions in the postoperative irradiation of breast cancer. Oncology 2005;69(3):214-223. (Pubitemid 41433580)
77. Suwinski R, Sowa A, Rutkowski T et al. Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients. Int J Radiat Oncol Biol Phys 2003;56(2):399-412. (Pubitemid 36542899)
78. Maciejewski BA, Skates S, Zajusz A et al. Importance of tumor size and repopulation for radiocurability of skin cancer. Neoplasma 1993;40(1):51-54. (Pubitemid 23138973)
79. Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 2009;19(6):683-697.
80. Xu Q, Yuan X, Liu G et al. Hedgehog signalingregulates brain tumor-initiating cell proliferation and portends shorter survival for patients with PTEN-coexpressing glioblastomas. Stem Cells 2008;26(12):3018-3026.
81. Scharpfenecker M, Kruse JJ, Sprong D et al. Ionizing radiation shifts the PAI-1/ID-1 balance and activates notch signaling in endothelial cells. Int J Radiat Oncol Biol Phys 2009;73(2):506-513.
82. Weinmaster G, Kopan R. A garden of Notch-ly delights. Development 2006;133(17):3277-3282.
83. Campa VM, Gutierrez-Lanza R, Cerignoli F et al. Notch activates cell cycle reentry and progression in quiescent cardiomyocytes. J Cell Biol 2008;183(1):129-141.
84. Ehrhart EJ, Segarini P, Tsang ML et al. Latent transforming growth factor beta1 activation in situ: quantitative and functional evidence after low-dose gamma-irradiation. FASEB J 1997;11(12):991-1002. (Pubitemid 27425901)
85. Barcellos-Hoff MH, Derynck R, Tsang ML et al. Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest 1994;93(2):892-899. (Pubitemid 2034135)
86. Barcellos-Hoff MH, Dix TA. Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol 1996;10(9):1077-1083. (Pubitemid 26299216)
87. Tian M, Schiemann WP. The TGF-beta paradox in human cancer: an update. Future Oncol 2009;5(2):259-271.
88. Itoh F, Itoh S, Goumans MJ et al. Synergy and antagonism between Notch and BMP receptor signaling pathways in endothelial cells. EMBO J 2004;23(3):541-551. (Pubitemid 38282386)
89. Masuda S, Kumano K, Shimizu K et al. Notch1 oncoprotein antagonizes TGF-beta/Smad-mediated cell growth suppression via sequestration of coactivator p300. Cancer Sci 2005;96(5):274-282. (Pubitemid 40895075)
90. Withers HR, Peters LJ, Taylor JM et al. Local control of carcinoma of the tonsil by radiation therapy: an analysis of patterns of fractionation in nine institutions. Int J Radiat Oncol Biol Phys 1995;33(3):549-562.
91. Rizzo P, Osipo C, Foreman K et al. Rational targeting of Notch signaling in cancer. Oncogene 2008;27(38):5124-5131.
92. van Es JH, van Gijn ME, Riccio O et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005;435(7044):959-963. (Pubitemid 40896322)
93. Farnie G, Clarke RB. Mammary stem cells and breast cancer-role of Notch signalling. Stem Cell Rev 2007;3(2):169-175. (Pubitemid 350129719)
94. Schwarz G. Ueber Desensibilisierung gegen Roentgen und Radium Strahlen. Muenchner Medizinische Wochenschrift 1909(24):1-2.
95. Holthusen H. Beiträge zur Biologie der Strahlenwirkung. Pflüger's Arch Ges Physiol 1921;187:1-24.
96. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9:539-549.
97. Hockel M, Schlenger K, Aral B et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56(19):4509-4515. (Pubitemid 26330463)
98. Brizel DM, Scully SP, Harrelson JM et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56(5):941-943.
99. Brizel DM, Sibley GS, Prosnitz LR et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38(2):285-289. (Pubitemid 27318643)
100. Fyles A, Milosevic M, Hedley D et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002;20(3):680-687. (Pubitemid 34111374)
101. Nordsmark M, Bentzen SM, Rudat V et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77(1):18-24.
102. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 2008;8(12):967-975.
103. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008;8(3):180-192.
104. Zölzer F, Streffer C. Increased radiosensitivity with chronic hypoxia in four human tumor cell lines. Int J Radiat Oncol Biol Phys 2002;54(3):910-920.
105. Chan N, Koritzinsky M, Zhao H et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 2008;68(2):605-614. (Pubitemid 351380090)
106. Sundfor K, Lyng H, Rofstad EK. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br J Cancer 1998;78(6):822-827. (Pubitemid 28418321)
107. Garcia-Barros M, Paris F, Cordon-Cardo C et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003;300(5622):1155-1159. (Pubitemid 36583102)
108. Seiwert TY, Cohen EE. Targeting angiogenesis in head and neck cancer. Semin Oncol 2008;35(3):274-285. (Pubitemid 351787696)
109. Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007;101(4):937-949. (Pubitemid 47040874)
110. Wu J, Long Q, Xu S et al. Study of tumor blood perfusion and its variation due to vascular normalization by anti-angiogenic therapy based on 3D angiogenic microvasculature. J Biomech 2009;42(6):712-721.
111. Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11(1):83-95. (Pubitemid 46075199)
112. Chen FH, Chiang CS, Wang CC et al. Radiotherapy decreases vascular density and causes hypoxia with macrophage aggregation in TRAMPC1 prostate tumors. Clin Cancer Res 2009;15(5):1721-1729.
113. Eriksen JG, Overgaard J. Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study. Radiother Oncol 2007;83(3):383-388. (Pubitemid 46907987)
114. Henke M, Mattern D, Pepe M et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;24(29):4708-4713.
115. Henke M, Laszig R, Rübe C et al. Erythropoeitin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. The Lancet 2003;262:1255-1260. (Pubitemid 37324251)
116. Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25(9):1027-1032.
117. Belenkov AI, Shenouda G, Rizhevskaya E et al. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther 2004;3(12):1525-1532. (Pubitemid 40136707)
118. Pajonk F, Weil A, Sommer A et al. The erythropoietin-receptor pathway modulates survival of cancer cells. Oncogene 2004;23(55):8987-8991. (Pubitemid 39657789)
119. Stüben G, Pottgen C, Knuhmann K et al. Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 2003;55(5):1358-1362. (Pubitemid 36338304)
120. Thews O, Koenig R, Kelleher DK et al. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 1998;78(6):752-756. (Pubitemid 28418307)
121. Santucci MA, Pierce JH, Zannini S et al. Erythropoietin increases the radioresistance of a clonal hematopoietic progenitor cell line expressing a transgene for the erythropoietin receptor. Stem Cells 1994;12(5):506-513. (Pubitemid 24278229)
122. Joiner B, Hirst VK, McKeown SR et al. The effect of recombinant human erythropoietin treatment on tumour radiosensitivity and cancer-associated anaemia in the mouse. Br J Cancer 1993;68(4):720-726. (Pubitemid 23301276)
123. Warburg O, Posener K, Negelein E. Ueber den Stoffwechsel der Tumoren. Biochem Z 1924;152:319-344.
124. DeBerardinis RJ, Lum JJ, Hatzivassiliou G et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7(1):11-20.
125. Li S, Li D. Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors. J Cell Mol Med 2007;11(6):1251-1262.